Eli Lilly (LLY) Shines In Third Quarter
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,244.40 -2.81%
Financial Fact:
Cost of sales, operating expenses, and other-net: 4.22B
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Cost of sales, operating expenses, and other-net: 4.22B
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Eli Lilly and Co. (NYSE: LLY) on Wednesday reported third quarter revenues of $5.56 billion, an increase of 7 percent. The company's third quarter revenues are ahead of the market consensus of $5.41 billion. The company's third quarter non-GAAP EPS of $1.20 is 18 cents above market estimates.
"Our performance in the third quarter once again was driven by volume-based sales growth, improving gross margins and tight control of operating expenses, allowing us to deliver very attractive earnings growth," Eli Lilly and Co. CEO John C. Lechleiter stated.
The profit for the Indianapolis-based pharmaceutical giant was $1.31 billion, above the $1.08 billion profit from the year ago quarter. Leading sales for Eli Lilly was the growth of the Zyprexa medication that increased sales by 3 percent in the third quarter. Zyprexa sales totaled $1.2 billion of the third quarter
Due to the strong third quarter numbers, Eli Lilly has revised its 2009 fiscal year EPS guidance to $4.30 to $4.40 on a pro-forma non-GAAP basis. The FY09 guidance is above the consensus estimate of $4.29.
"These results are evidence of the strength of our current operations as we implement our new operating model, streamline our organization and take measures to accelerate the flow of new medicines through our pipeline," added Lechleiter.
Eli Lilly is currently at $35.24 before the markets open today.
"Our performance in the third quarter once again was driven by volume-based sales growth, improving gross margins and tight control of operating expenses, allowing us to deliver very attractive earnings growth," Eli Lilly and Co. CEO John C. Lechleiter stated.
The profit for the Indianapolis-based pharmaceutical giant was $1.31 billion, above the $1.08 billion profit from the year ago quarter. Leading sales for Eli Lilly was the growth of the Zyprexa medication that increased sales by 3 percent in the third quarter. Zyprexa sales totaled $1.2 billion of the third quarter
Due to the strong third quarter numbers, Eli Lilly has revised its 2009 fiscal year EPS guidance to $4.30 to $4.40 on a pro-forma non-GAAP basis. The FY09 guidance is above the consensus estimate of $4.29.
"These results are evidence of the strength of our current operations as we implement our new operating model, streamline our organization and take measures to accelerate the flow of new medicines through our pipeline," added Lechleiter.
Eli Lilly is currently at $35.24 before the markets open today.
You May Also Be Interested In
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
Create E-mail Alert Related Categories
Earnings, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
